• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

GLP-1 startup i2o looks to revive diabetes drug-eluting implant from Intarcia

September 5, 2023 By Sean Whooley

Intarcia Therapeuticsi2o Therapeutics says it acquired the diabetes-treating assets of one-time medtech unicorn Intarcia Therapeutics.

The Boston-based company acquired and integrated Intarcia’s proprietary assets and made a big personnel move. With CEO Ravi Srinivasan moving onto other opportunities, i2o named Kurt Graves as chair, president and CEO.

Graves previously served as executive chair of the i2o board, taking that position in August 2021. He also previously served as chair, president and CEO of Intarcia.

At one point, Intarcia held the label of potential game-changer in diabetes. The company developed a type 2 diabetes drug and a proprietary six-month GLP-1 implant for delivery.

Investors valued the company at more than $5 billion. But despite the hype, the FDA refused to allow Intarcia’s ITCA 650 on the market. Trials identified that it might cause acute kidney issues, while the company ran into some production challenges.

Intarcia received a lifeline earlier this year when the FDA allowed it to request a public advisory committee hearing after two previous rejections.

i20, a startup founded in 2019, also said it raised a $46 million Series A round with “top-tier” biotech investors.

More about the potential i2o lifeline for Intarcia

i20 itself has active work to advance the ionic liquids technology on a GLP-1 asset. GLP-1, a drug class including Ozempic and Wegovy, has cast a shadow of doubt over diabetes technology of late. This therapeutic class, a glucagon-like peptide 1, has proven to lead to improved blood sugar control and weight loss.

Analysts even recently trimmed some forecasts on sales to reflect increased pressure on diabetes technology as a whole with GLP-1 updates. The current trend impacted market responses to the likes of Insulet and Embecta in this most recent quarter. It even had an impact on Intuitive Surgical and its surgical robot for bariatric procedures.

Vivani Medical is another company looking to penetrate the market with a GLP-1-delivering implant.

i20’s Intarcia asset acquisition covers pipeline assets in the cardiometabolic space. It includes long-acting GLP-1s, Amylin, Glucagon and PYY. The company also acquired ITCA 650 and the Medici implant technology platform. Intarcia’s long-heralded but maligned platform has a public hearing before an FDA advisory committee on Sept. 21.

“The cardiometabolic assets and novel delivery platforms we have at i2o are important at a time when global policy and health officials are increasingly concerned by soaring diabetes and obesity prevalence rates and the massive implications that poor glucose and weight control will have on healthcare systems, societies, and global economies for decades to come,” said new CEO Graves. “At i2o, our ultimate goal is to be an important part of the novel GLP-1 based combination products and innovative drug delivery solutions that are needed to raise the standards of care, address widespread unmet needs around poor control and poor adherence, and to help remove the barriers to access, affordability, and supply that are needed to help millions of patients.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants, Mergers & Acquisitions, Personnel, Regulatory/Compliance Tagged With: i2o Therapeutics, Intarcia Therapeutics, Personnel Moves

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS